The economics of follow-on drug research and development

@article{Dimasi2004TheEO,
  title={The economics of follow-on drug research and development},
  author={Joseph A Dimasi and Cherie Paquette},
  journal={PharmacoEconomics},
  year={2004},
  volume={22},
  pages={1-14}
}
Objectives: The development of so-called ‘me-too’, or ‘follow-on’, drugs by the pharmaceutical industry has been viewed by some as duplicative and wasteful, while others have argued that these drugs often provide needed therapeutic options and inject some price competition into the marketplace. This study examines data on the trends in the speed with which competitive entry has occurred in the pharmaceutical marketplace and the competitive nature of the industry’s development of these drugs… CONTINUE READING
18 Citations
28 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

The changing nature of NCE pricing of second and subsequent entrants

  • A Towse, T. Leighton
  • Risk and return in the pharmaceutical industry…
  • 1999
Highly Influential
11 Excerpts

Benefits and costs of newer drugs

  • FR Lichtenberg
  • National Bureau of Economic Research Working…
  • 2002
Highly Influential
6 Excerpts

Health insurance and the growth in pharmaceutical expenditures

  • PM Danzon, MV Pauly
  • J Law Econ 2002;
  • 2002
Highly Influential
3 Excerpts

AHRQ comparative study agenda should emphasize lit reviews – McClellan

  • F-D-C Reports
  • Pink Sheet 2004 May 31;
  • 2004

CMS will focus on value, not price, of medicines, McClellan pledges

  • F-D-C Reports
  • Pink Sheet 2004 Mar 29; 66 (13): 9-10…
  • 2004

Similar Papers

Loading similar papers…